ArticleGeneral published source
- Source type
- Article
- Access type
- Publisher
- Publisher
- Solid Biosciences
- Date
- 2026-06-22
- Added
- 2026-06-27
Trust profile
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
Backgroundbrief1 reference
A Very Young Duchenne Patient Was Dosed With Investigational Microdystrophin Gene Therapy
Roles: Background
Show section-level references
Claims supported
No reusable evidence claims are currently attached to this source.
Related studies
No structured study record is currently attached to this source.
Related sources
GovernmentU.S. health regulator
FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease
Canonicalized from rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 2 connections
GovernmentU.S. health regulator
FDA: First Over-the-Counter Continuous Glucose Monitor for Children
Canonicalized from rapid brief fda-otc-cgm-children-dexcom-stelo.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
ArticleGeneral published source
Regenxbio: Alignment with FDA on path forward for Navsunli BLA resubmission
Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.
- Trust score
- 60
- Publisher
- Regenxbio
- Access
- Publisher
- Usage
- 1 connection
ArticleGeneral published source
Reuters: FDA reverses course on Regenxbio rare-disease gene therapy
Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 2 connections
Topic tags
medicinegene-therapyrare-diseasepediatric-medicineduchenne-muscular-dystrophy